MaxCyte, Inc. - Result of Offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
Result of Offering
Gross proceeds from the Placing and Subscription of
Oversubscribed fundraise led by new international specialist healthcare crossover investors
The Placing was significantly oversubscribed. The Issue Price represents a discount of approximately 10 per cent. to the Company's mid-market closing price as at
Completion of the Offering remains subject, inter alia, to the passing of the Resolutions at the Special Meeting to be held on
A circular to shareholders convening the Special Meeting is expected to be posted by
"I am delighted with the outcome of this financing round and, in particular, am pleased to welcome specialist investors
Application will be made to the
Upon Admission, the Placing Common Stock and Sofinnova Subscription Common Stock will trade in the Company's new restricted line of Common Stock under the symbol MXCL. The Placing Common Stock and Sofinnova Subscription Common Stock as represented by Depository Interests, will be held in the CREST system and will be segregated into a separate trading system within CREST identified with the marker "REG S CAT 3/144A" and ISIN USU575803072. The Company also maintains an unrestricted line of Common Stock trading under the existing symbol MXCT. The Casdin Subscription Common Stock will trade under the existing symbol MXCT and ISIN US57777K1060.
Following Admission, the total issued stock capital of the Company will be 76,585,006. The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is expected to be 66,684,917 and the number of restricted shares of Common Stock trading under the symbol 'MXCL' is expected to be 9,900,089.
Related party transaction
The capitalised terms used in this announcement have the meaning set out in the announcement made by the Company at 5.39 p.m. yesterday. All references to times and dates in this announcement are to times and dates in
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward looking statements, many of which are beyond the control of the Company. In particular, the outcome of clinical trials (including, but not limited to the Company's CARMA trial) may not be favourable or potential milestone payments associated with the Company's licenced programmes may not be received. In addition, other factors which could cause actual results to differ materially include risks associated with vulnerability to general economic and business conditions, competition, regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
These materials may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into
This information is provided by RNS, the news service of the
Quick facts: MaxCyte Inc
Market Cap: £169.25 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE